that must be included in the Notified Body’s assessment. Familiarity with these components will facilitate effective communication with the Notified Body and assist in meeting their documentation expectations. The General Safety and Performance Requirements (GSPR) as outlined in Annex II of the EU MDR must be addressed comprehensively.

• GSPR: Review each requirement outlined in Annex I closely. Ensure your clinical evaluation, risk management, and post-market surveillance plans align with GSPR.
• Interrelation of Components: Understand how the medicinal product component integrates with the medical device, including its intended use and performance characteristics.
• Notified Body Selection: Choose a competent Notified Body that is designated under the EU MDR for your device’s specific classification.

The understanding of these elements will form the basis for effective data collection and documentation. Taking the time to review and align your product characteristics with the expectations of the Notified Body is perhaps the most critical step prior to actual submission.

Step 2: Preparing the Required Documentation

The next step involves preparing the necessary documentation to support the Notified Body Opinion. The documentation should be comprehensive yet concise, directly correlating with the findings derived from the clinical evaluation, GSPR, and post-market commitments.

Specific documentation requirements may vary depending on the Notified Body, but generally will include:

• Clinical Evaluation Report (CER): A well-structured CER that confirms the safety and effectiveness of the combination product. It should cite relevant literature and possibly include clinical trial data, if available.
• Risk Management File: Ensure that your risk management process adheres to ISO 14971 standards and is reflective of both the device and the medicinal components.
• Labeling and Instructions for Use: Prepare clear and detailed labeling that narrates the use of the combination product while indicating the medicinal component.
• Post-Market Surveillance Plan: This plan must outline how the product will be monitored after it is marketed to ensure safety and performance. Emphasizing procedures to gather feedback from users and healthcare providers will be beneficial.

To provide adequate information for the Notified Body, ensure that all strands of documentation interlink, stressing their relevance to the safety requirements specified in the regulation. Furthermore, maintain concise scientific language throughout, using formal terminology that reflects the product’s efficacy and safety.

Step 3: Engaging with a Notified Body

Once documentation is ready, practitioners should establish effective communication with the selected Notified Body. This stage is critical for aligning expectations and clarifying the submission process. It is advisable to conduct a pre-submission discussion with the Notified Body to confirm the insights and data you will be submitting in the application for the NBOp under Article 117.

Diligently prepare for any preliminary questions or concerns that the Notified Body may raise. This type of engagement can facilitate a streamlined review process and increase the likelihood of approval.

• Pre-Submission Meeting: Organize a pre-submission meeting to discuss your application and address any procedural questions. It is an opportunity to understand specific safety elements that the Notified Body may focus on during their review.
• Clarification Requests: Be responsive to any requests for clarification or additional information. Timely responses show professionalism and can expedite the NBOp process.
• Documentation Layout & Submission: Adhere to specified formats and procedures for submission. Each Notified Body has its own submission guidelines which must be followed closely.

Your proactive involvement often impacts the outcomes of the review. It’s important to foster an open line of communication while maintaining professionalism throughout the interaction.

Step 4: Review Process Observations

Understanding and anticipating the review process path the Notified Body will take is essential to effectively managing the timeline and preparing for potential revisions. During the evaluation of the submitted documentation, there are several core activities undertaken by the Notified Body.

Typically, the review process includes the following stages:

• Initial Review: At this stage, the Notified Body will confirm all necessary documentation has been received and is appropriately structured. They will assess whether the submitted materials meet the requirements set forth in the EU MDR.
• Technical Evaluation: Technical evaluators will analyze technical reports, including the clinical evaluation report and risk management file, focusing on compliance with GSPR. Ensure your documentation is comprehensive enough to withstand this scrutiny.
• Expert Appeal and Consultation: The Notified Body may consult with external experts on certain complex aspects that require specialized knowledge. They may also seek input on clinical efficacy and safety data.

As the holder of the application, it is beneficial to stay engaged during the evaluation phase. Be prepared for ongoing dialogue as they may request additional data or clarification that could influence their opinion.

Step 5: Handling Feedback and Revisions

Upon completing their review, the Notified Body will produce feedback regarding the application for the NBOp. If approved, they will issue a formal opinion favorable to Article 117. However, if the opinion is unfavorable, understanding the grounds for rejection and effectively addressing concerns will be vital for a successful re-application.

Depending on the findings, you will need to:

• Addressing Nonconformities: If any findings indicate non-compliance with GSPR, undertake a thorough investigation and revision of the documentation, ensuring that all concerns are addressed.
• Resubmission Process: Understand the resubmission process for your Notified Body, ensuring all revised documents are accurately formatted and resubmitted according to protocol.
• Continuous Engagement: Maintain continuous communication with the Notified Body during this phase. This transparency often mitigates misunderstandings and aids in a smoother path to approval.

Employing a careful and systematic approach when responding helps to solidify the integrity of your product in the eyes of the Notified Body and conveys your commitment to compliance with the EU MDR guidelines.

Step 6: Post-Approval Commitments

After successfully receiving the Notified Body Opinion, certain post-approval commitments must be adhered to and monitored continuously. Maintenance of compliance with EU regulations does not cease with the issuance of approval; it is an ongoing process that encompasses several responsibilities.

• Post-Market Surveillance (PMS): Implement and regularly review your post-market surveillance plan to ensure ongoing compliance with safety standards. This should include continuous data collection from users and health care providers to assess the performance and safety of the device.
• Periodic Safety Update Reports (PSUR): When applicable, prepare and submit periodic safety update reports as dictated by regulatory authorities on the safety profile of the product, including adverse events associated with its use.
• Adaptation to Regulatory Changes: Stay informed of any changes within the regulatory landscape to ensure timely adaptation of compliance frameworks and practices.

In essence, successfully obtaining a Notified Body Opinion under Article 117 requires meticulous preparation, thorough documentation, proactive communication, and ongoing compliance management. By adhering to the steps outlined in this tutorial guide, regulatory professionals responsible for product compliance can effectively navigate the processes required to meet the requirements of the EU medical device landscape.

In conclusion, leveraging EU MDR consulting services can significantly enhance an organization’s preparedness and ability to meet regulatory compliance requirements for combination products, ensuring not only market access but also patient safety and product efficacy.